About Us
MedicaSafe has been funded by the National Institutes of Health to curb medication misuse and to improve patient compliance.
Our Mission
MedicaSafe specializes in creating technology to manage high-risk medications. Our first product focuses on addressing the opioid epidemic by targeting treatment compliance, limiting diversion, and giving peace of mind to prescribers through insight into patient behaviors. With these targets our systems allow for earlier intervention by the clinician, leading to safer outcomes for all.
Meet Our Team
Leadership

Matt Ervin
Chief Executive Officer
Matt Ervin founded MedicaSafe after collaborating on NIH-funded projects to improve medication therapy management. Previously Matt founded Plum Voice, the leading independent SaaS platform for IVR, VoiceXML, and speech dialogs. Matt has 17 years of product management experience. He holds a B.A. from Harvard University in Physics and an M.S. from Harvard in Applied Sciences.

Anand Mattai, MD
Chief Medical Officer
Board certified in Psychiatry, Dr. Mattai
pursued a clinical research fellowship at
the National Institutes of Mental Health
where he served as an investigator on
several studies. He previously held
positions as Medical Officer at the FDA
Center for Drug Evaluation and Research
and as Medical Director at Vanda
Pharmaceuticals.
A summa cum laude graduate of Knox
College and a graduate of the University
of Iowa Carver College of Medicine, he
completed his psychiatric residency at
Creighton University/University of
Nebraska College of Medicine.

Thomas Lau
Chief Operating Officer
Tom’s 18 years of finance and operations experience include managing and launching a software business funded by Dow Jones and working as an investment executive at JP Morgan and Citigroup. He holds a B.A. from Yale University in Economics.

Colin Steel
Chief Technology Officer
Colin’s past work includes development of web applications and services for PricewaterhouseCoopers and JDM Interactive. He is an experienced instructor, having taught software design at CUNY Baruch for 15 years. He holds a B.A. in Computer Science from Columbia University.
Advisors

Andrew Saxon, MD
Advisory Board
Dr. Saxon has more than a quarter century of experience as a clinical and research addiction psychiatrist. Dr. Saxon is board certified with added qualifications in addiction psychiatry by the American Board of Psychiatry and Neurology. Dr. Saxon sits on the editorial boards of the journals, Drug and Alcohol Dependence and General Hospital Psychiatry and is section editor for substance use disorders for UpToDate. Dr. Saxon’s current research work is supported by the VA, the Department of Defense, and the National Institute on Drug Abuse and involves pharmacotherapies and psychotherapies for alcohol, cocaine, tobacco, and opioid use disorders as well work in co- occurrence of substance use disorders and posttraumatic stress disorder and on reducing homelessness.

Esther Dyson
Advisory Board
Esther Dyson is executive founder of the Way to Wellville, a ten-year, nonprofit evidence-generating project devoted to defining and refining models for investing in community health (not health *care*) that return profits to investors and health to the participants and their communities. Dyson is actively involved in overall policy and fundraising for Way to Wellville. Esther invests in and nurtures start-ups, with a recent focus on health care (somewhat constrained to avoid conflicts with Wellville). On the health side, notable investments include 23andMe (also a director), Clover Health, MedicaSafe (advisory board), Nuna, Omada Health, PatientsLikeMe, Tocagen, Wellpass (director).

Ross Fishman, PhD
Advisory Board
Ross Fishman, Ph.D., CGP is a New York State licensed psychologist. He is co-founder and President of Innovative Health Systems, an outpatient substance use disorder clinic in White Plains NY which was established in 1985. Following a post-doctoral fellowship and instructorship in the Department of Psychiatry of Albert Einstein College of Medicine at Montefiore Hospital and Medical Center, he served as Director of Evaluation at the Bureau of Alcoholism Services, NYC Department of Mental Health, Mental Retardation and Alcoholism Services. He was an Adjunct Associate Professor of Psychology at the Queens College of the City University of New York (CUNY). Dr. Fishman later served as the Director of Education and Training at the National Council on Alcoholism, New York City Affiliate. He has served as voluntary faculty in the departments of psychiatry at Cornell University Medical College and New York Medical College. For many years he was on the affiliate medical staff at Rye Psychiatric Center in Rye, NY. Dr. Fishman holds the American Psychological Association’s Certificate of Proficiency in the Treatment of Alcoholism and Other Psychoactive Substances and is a member of the Addiction Division of the New York Sate Psychological Association and the American Group Psychotherapy Association. He volunteers in his community as a member and past chair of the Town of Greenburgh Police/Community Advisory Committee, as the substance use disorder specialist on a federal prevention grant to the Village of Ardsley and as a member of Congresswoman Nita Lowey’s Opioid Study Group. Dr. Fishman, author of Alcohol and Alcoholism, Chelsea House Publications, is a frequent speaker on opioid dependence treatment and the opioid crisis; harm reduction psychotherapy; and divorce contemplation, a new approach to divorce prevention.